Glenmark Pharmaceuticals Initiates Class II Recall for Carvedilol Tablets Over Nitrosamine Impurity
Glenmark Pharmaceuticals Inc., USA, has initiated a Class II recall for Carvedilol Tablets due to N-Nitroso Carvedilol I impurity exceeding acceptable limits. This regulatory action highlights critical CGMP deviations at the manufacturing site in India, impacting supply chain stability for this essential cardiovascular drug and demanding immediate risk assessment from procurement and regulatory teams.
Glenmark Initiates Class II Recall for Carvedilol Tablets Due to Nitrosamine Contamination
Glenmark Pharmaceuticals Inc., USA, has initiated a Class II voluntary recall, D-0578-2025, for specific lots of its Carvedilol Tablets, USP, 12.5 mg. This critical regulatory action, initiated on August 7, 2025, stems from identified Current Good Manufacturing Practice (CGMP) deviations, specifically the presence of N-Nitroso Carvedilol I impurity at levels exceeding the current Acceptable Intake (AI) limit. The recall affects 6,432 bottles of the 12.5 mg dosage, identified under Lot#: 19243202 with an expiration date of July 31, 2026, and distributed nationwide across the USA. For procurement directors, this means an immediate need to quarantine and return affected stock, while simultaneously assessing inventory levels and potential shortfalls for a widely prescribed cardiovascular medication. Regulatory affairs heads must ensure all internal procedures align with FDA recall protocols and prepare for increased scrutiny on nitrosamine testing for all incoming active pharmaceutical ingredients (APIs) and finished products. This event underscores the persistent challenge of nitrosamine control within the global pharmaceutical supply chain, demanding proactive risk management.
Regulatory Implications of N-Nitroso Carvedilol I Exceeding Acceptable Intake Levels
The core issue driving Glenmark's Carvedilol recall is the detection of N-Nitroso Carvedilol I, a nitrosamine impurity, above the FDA’s established Acceptable Intake (AI) level. Nitrosamines are classified as probable human carcinogens, and their presence in drug products, even at trace levels, triggers significant regulatory concern. This Class II classification indicates that exposure to the recalled product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. For regulatory affairs teams, this necessitates a comprehensive review of their own nitrosamine risk assessment strategies, including potential formation pathways, impurity control, and testing methodologies for all products, particularly those with similar chemical structures or manufacturing processes. Supply chain VPs must recognize that such CGMP deviations at a manufacturing site, even if the recalling firm is the US entity, can lead to broader regulatory actions, including potential import alerts or further product withdrawals, impacting long-term supply stability. Business development executives should note that sustained compliance issues can erode market confidence and create opportunities for competitors with robust quality systems.
Supply Chain Disruption: Impact on Carvedilol Availability and Procurement Strategies
The recall of Glenmark's Carvedilol Tablets, USP, 12.5 mg, directly impacts the availability of this critical beta-adrenergic blocker used in the management of hypertension and heart failure. With 6,432 bottles of the 500-count size (NDC 68462-164-05) affected and distributed nationwide in the USA, procurement directors face an immediate need to secure alternative supplies. This volume represents a tangible disruption for pharmacies and healthcare providers relying on Glenmark as a supplier for ANDA078251. Supply chain VPs must activate contingency plans, assessing current stock levels across their distribution networks and identifying any single points of failure in their Carvedilol sourcing. The recall, categorized as 'Voluntary: Firm initiated,' indicates Glenmark's proactive response, but the underlying CGMP deviation points to systemic quality control challenges at the manufacturing level. This situation underscores the imperative for robust supplier qualification programs that include rigorous audits for nitrosamine control and overall CGMP adherence, especially for generic medications where multiple manufacturers often exist. Failure to address this swiftly could lead to drug shortages, impacting patient care and incurring significant reputational and financial costs.
Manufacturing Origin and Global Compliance Scrutiny for Glenmark Pharmaceuticals
The Carvedilol Tablets subject to this recall were manufactured by Glenmark Pharmaceuticals Ltd in Colvale-Bardez, Goa, 403513, India, for Glenmark Pharmaceuticals Inc., USA, located in Mahwah, NJ 07430. This geographical distinction is crucial for regulatory affairs and supply chain leaders. The CGMP deviations identified, leading to the nitrosamine impurity, originate from the Indian manufacturing facility. This places the Goa site under heightened scrutiny from the FDA, potentially impacting future approvals or inspections for other products manufactured there. For procurement directors, this means evaluating not just the immediate product recall but also the broader compliance status of the Indian facility for any other APIs or finished dosage forms sourced from it. A single compliance issue can trigger a cascade of regulatory actions, including potential FDA import alerts for products originating from the affected site. Business development executives must consider the reputational risk associated with sourcing from facilities with recurring compliance challenges, as this can affect market access and partner confidence globally. Diversifying manufacturing locations and conducting thorough due diligence on international sites are paramount to mitigate such risks.
Navigating Future Supply: Strategies for Identifying and Qualifying Alternative Carvedilol Sources
Given the ongoing Class II recall of Glenmark's Carvedilol, procurement directors and supply chain VPs must prioritize identifying and qualifying alternative suppliers to ensure uninterrupted access to this vital medication. While specific alternative suppliers are not detailed in the available intelligence, the market for generic Carvedilol (RXCUI: 200031, 200032, 200033, 686924) typically includes multiple manufacturers. The immediate action involves reviewing existing supplier portfolios to identify pre-qualified or readily qualifiable alternatives. This process demands a rapid but thorough assessment of their regulatory history, manufacturing capabilities, and nitrosamine control strategies. Qualification timelines can range from several months to over a year, depending on the complexity of the product and the stringency of internal quality systems. Regulatory affairs teams must be prepared to support accelerated qualification processes, ensuring that all new sources meet stringent FDA requirements, including comprehensive nitrosamine risk assessments and testing. Business development executives should explore strategic partnerships with manufacturers demonstrating robust quality systems and a clear track record of compliance, thereby strengthening their market position and reducing reliance on single-source suppliers for critical drugs.
Immediate Actions and Long-Term Regulatory Outlook for Glenmark
For Glenmark Pharmaceuticals, the immediate priority is to effectively manage the ongoing Class II recall (D-0578-2025) and address the underlying CGMP deviations that led to the N-Nitroso Carvedilol I impurity. This involves a thorough root cause analysis, implementation of corrective and preventive actions (CAPAs) at the Colvale-Bardez, Goa manufacturing facility, and transparent communication with the FDA. For regulatory affairs professionals monitoring Glenmark, this event signals potential for increased FDA oversight, including future inspections of the Indian facility. The long-term outlook for Glenmark will depend heavily on the efficacy and timeliness of their remediation efforts. Failure to adequately address the CGMP deviations could lead to more severe regulatory consequences, such as an FDA Warning Letter, placement on Import Alert for products from the Goa facility, or even consent decrees. Supply chain VPs should anticipate potential delays or restrictions on other products sourced from Glenmark's Indian operations until the FDA is satisfied with their compliance improvements. This event serves as a critical reminder for all industry stakeholders that maintaining impeccable quality control and CGMP adherence is non-negotiable for market access and sustained business operations in the global pharmaceutical landscape.